ライフサイエンスコーパス: type 2 diabetes

1 m microvascular complications in adults with type 2 diabetes.

2 ontribute to glucolipotoxicity that leads to type 2 diabetes.

3 ys is a relatively new strategy for treating type 2 diabetes.

4 tion and may contribute to increased risk of type 2 diabetes.

5 ng disorder, cocaine addiction, obesity, and type 2 diabetes.

6 ure of chronic disorders such as obesity and type 2 diabetes.

7 ways easy to distinguish LADA from type 1 or type 2 diabetes.

8 als with prediabetes who were diagnosed with type 2 diabetes.

9 er-2 inhibitor approved for the treatment of type 2 diabetes.

10 ic lipid deposition, insulin resistance, and type 2 diabetes.

11 logs a useful and safe treatment modality in type 2 diabetes.

12 syndrome and 1.37 (1.03-1.82; P = 0.021) for type 2 diabetes.

13 pression patterns of neutrophil receptors in type 2 diabetes.

14 5 as a potential target to prevent and treat type 2 diabetes.

15 ammation plays a key role in both type 1 and type 2 diabetes.

16 ndividuals and reduces comorbidities such as type 2 diabetes.

17 ose-lowering medication in participants with type 2 diabetes.

18 fy this important issue in the management of type 2 diabetes.

19 n of risk of complications for patients with type 2 diabetes.

20 nt a new class of therapeutic agent to fight type 2 diabetes.

21 emorrhagic, and 79578 other), and 67914 from type 2 diabetes.

22 over 2 y using MRI in overweight adults with type 2 diabetes.

23 ts is described as a potential treatment for type 2 diabetes.

24 y studied in persons with type 1 diabetes or type 2 diabetes.

25 isease, and dysregulation of inflammation in type 2 diabetes.

26 T cell MHP was not detected in subjects with type 2 diabetes.

27 simplistically lumped into the large pool of type 2 diabetes.

28 control participants and five patients with type 2 diabetes.

29 pathway signaling in islets from donors with type 2 diabetes.

30 sed blood levels of glucose in patients with type 2 diabetes.

31 rative effectiveness of oral medications for type 2 diabetes.

32 waist-to-hip ratio, and an increased risk of type 2 diabetes.

33 nabled development of new medicines to treat type 2 diabetes.

34 optosis is an important disease mechanism in type 2 diabetes.

35 spectroscopy in 449 individuals at risk for type 2 diabetes.

36 OSA is associated with STDR in patients with type 2 diabetes.

37 e assessed this risk long term in women with type 2 diabetes.

38 -years, we identified 4347 cases of incident type 2 diabetes.

39 tion, with relevance to human physiology and type 2 diabetes.

40 ex and all-cause mortality among people with type 2 diabetes.

41 a strategy that may reduce beta-cell loss in type 2 diabetes.

42 production (HGP) represents a key feature of type 2 diabetes.

43 ls is a major contributor to the etiology of type 2 diabetes.

44 n maintain glycemic control in patients with type 2 diabetes.

45 ss of ovarian estrogens is a risk factor for type 2 diabetes.

46 or other obesity-related morbidity, such as type 2 diabetes.

47 rget patient population includes adults with type 2 diabetes.

48 s of DR in many but not in all patients with type 2 diabetes.

49 apine often induce excessive weight gain and type 2 diabetes.

50 sured in peripheral blood in the etiology of type 2 diabetes.

51 y yield insights into the pathophysiology of type 2 diabetes.

52 uld serve as potential drug targets to treat type 2 diabetes.

53 and PDR) with incident CVD in patients with type 2 diabetes.

54 enia is associated with an increased risk of type 2 diabetes.

55 s that enhance GLP-1 levels in patients with type 2 diabetes.

56 pectives in the pharmacological treatment of type 2 diabetes.

57 h as the prevention of metabolic syndrome or type 2 diabetes.

58 et diabetes of the young form 3 (MODY 3) and type 2 diabetes.

59 Of these patients, most (98%) had type 2 diabetes.

60 are increasingly being used as treatment for type 2 diabetes.

61 in fasting plasma insulin level and risk of type 2 diabetes.

62 ociated with an increased risk of developing type 2 diabetes.

63 x and lysosomal staining in human samples of type 2 diabetes.

64 importance for the treatment of obesity and type-2 diabetes.

65 In a subgroup of patients with type 2 diabetes, a decrease in fasting insulin (MD -7 mi

66 416 patients aged >/=25 years with type 1 or type 2 diabetes, a serum creatinine (SCr) level of 1.3-3

67 Type 2 diabetes accounts for more than 90% of patients w

68 anagement of hyperglycaemia in patients with type 2 diabetes admitted to general medicine and surgery

69 ased drugs in the treatment of patients with type 2 diabetes admitted to hospital has not been extens

70 ariants associated with an increased risk of type 2 diabetes affect the function of a monocarboxylate

71 In 1,259 type 2 diabetes-affected case subjects and 5,765 control

72 ed end point trial, consenting patients with type 2 diabetes aged >18 years, with waist circumference

73 articipants were insulin-naive patients with type 2 diabetes, aged 18 years and older, who had insuff

74 For example, some hypertension and type 2 diabetes alleles will be associated with BMI in s

75 Young-onset type 2 diabetes also affects more individuals of working

76 and novel IAPP analogs for the management of type 2 diabetes, Alzheimer's disease, or other diseases

77 Program (DPP), a trial for the prevention of type 2 diabetes among high-risk individuals, we quantifi

78 cose metabolism, including increased risk of type 2 diabetes among nonpregnant individuals.

79 The incidences of both type 1 and type 2 diabetes among youths increased significantly in

80 RPRETATION: In a population of patients with type 2 diabetes and a broad cardiovascular risk profile,

81 SA, enrolling patients aged 18-80 years with type 2 diabetes and a random blood glucose concentration

82 usions In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular d

83 reased in skeletal muscle from patients with type 2 diabetes and are decreased following endurance tr

84 ic component of obesity, insulin resistance, type 2 diabetes and associated morbidities.

85 flammation has been associated with incident type 2 diabetes and atherosclerotic cardiovascular disea

86 BMI), a measure of abdominal adiposity, with type 2 diabetes and CHD through the potential intermedia

87 ential association among these precursors of type 2 diabetes and cognitive dysfunction.

88 rns have been associated with lower risks of type 2 diabetes and coronary artery disease, but their r

89 abdominal adiposity has been associated with type 2 diabetes and coronary heart disease (CHD).

90 s Network, we apply each feature of PLATO to type 2 diabetes and demonstrate how PLATO can be used to

91 Patients with type 2 diabetes and DME or PDR have an increased risk of

92 pants were selected based on the presence of type 2 diabetes and either prevalent CVD or CVD risk fac

93 adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but

94 de 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were re

95 beta-cells and down-regulated in type 1 and type 2 diabetes and in infiltrating activated immune cel

96 Type 2 diabetes and insulin resistance are associated wi

97 tion of arsenic exposure and metabolism with type 2 diabetes and insulin resistance.

98 utcomes of metformin use in populations with type 2 diabetes and moderate to severe chronic kidney di

99 ls of methionine and BCAAs, in patients with type 2 diabetes and NAFLD.

100 peutic targets in metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease.

101 ex (BMI), physical activity, alcohol intake, type 2 diabetes and parity, use of hormone replacement t

102 prevent or delay progression of early-stage type 2 diabetes and prediabetes.

103 iflozin reduced albuminuria in patients with type 2 diabetes and prevalent albuminuria.

104 ns associated with Alzheimer's, Parkinson's, type 2 diabetes and prion diseases.

105 Cell phagocytosis is impaired in type 2 diabetes and requires RvE1 for activation.

106 has long-term benefits for the prevention of type 2 diabetes and that arachidonic acid is not harmful

107 omising causal paths to and from glucose and type 2 diabetes and underline the value of additional in

108 l effect of each metabolite with glucose and type 2 diabetes and vice versa.

109 le decreased risk of Parkinson's disease and type-2 diabetes and an increased risk of pregnancy loss.

110 meta-analysis of prospective cohort studies (type 2 diabetes), and a prospective cohort study (dental

111 se measurements captured by individuals with type 2 diabetes, and against predictions generated by ex

112 Plasma fetuin-A is associated with type 2 diabetes, and AHSG, the gene encoding fetuin-A, h

113 lin resistance, obesity, metabolic syndrome, type 2 diabetes, and an adverse lipid profile.

114 of obesity, coronary heart disease, stroke, type 2 diabetes, and asthma.

115 ders and it tightly associates with obesity, type 2 diabetes, and cardiovascular disease.

116 n of this score with cardiometabolic traits, type 2 diabetes, and CHD was tested in a mendelian rando

117 py in reducing hyperglycemia in persons with type 2 diabetes, and has been associated with reduced mo

118 mplicated in the beta cells of patients with type 2 diabetes, and in the beta cells of obese diabetic

119 rtriglyceridemia, severe insulin resistance, type 2 diabetes, and nonalcoholic steatohepatitis (NASH)

120 genes are relevant in the pathophysiology of type 2 diabetes, and that mitochondrial BCAA management

121 Both type 1 and type 2 diabetes are associated with long-term complicati

122 Obesity and type 2 diabetes are associated with low-grade inflammati

123 Patients with type 2 diabetes are at high risk of cardiovascular disea

124 ditions including heart disease, stroke, and type 2 diabetes are leading causes of preventable death.

125 Apolipoprotein E4 (E4) and type 2 diabetes are major risk factors for cognitive dec

126 Metabolic diseases such as obesity and type 2 diabetes are recognized as independent risk facto

127 Obesity and type 2 diabetes are significant risk factors for maligna

128 ith exenatide to usual care in patients with type 2 diabetes are unknown.

129 raglutide on renal outcomes in patients with type 2 diabetes are unknown.

130 Biomarkers for type 2 diabetes are useful for prediction and interventi

131 fic and tailored management of patients with type 2 diabetes, as has been shown in patients with matu

132 ranscription factors and coregulators at the type 2 diabetes associated PPARG locus.

133 Type 2 diabetes-associated genetic loci were significant

134 ng the patients in the surgery group who had type 2 diabetes at baseline, type 2 diabetes remitted in

135 We excluded participants with type 2 diabetes at baseline.

136 Among patients with type 2 diabetes at high risk for cardiovascular events,

137 etitian as part of lifestyle intervention in type 2 diabetes, but further randomized studies are warr

138 models of type 1 diabetes and two models of type 2 diabetes by adeno-associated virus delivery of re

139 focused on Spry2-a gene implicated in human type 2 diabetes by genome-wide association studies but w

140 ed by obesity, and are at risk of developing type 2 diabetes, cardiovascular disease and related meta

141 proved HbA1c and bodyweight in patients with type 2 diabetes compared with placebo, and showed a simi

142 nd comorbidities was higher among those with type 2 diabetes compared with type 1, but frequent in bo

143 k individuals are twice as likely to develop type 2 diabetes compared with white individuals, and the

144 ently, IL-12 emerged as a critical player in type 2 diabetes complications.

145 bolic multimorbidity (ie, at least two from: type 2 diabetes, coronary heart disease, and stroke) in

146 Because few insulin-treated patients with type 2 diabetes currently use CGM, these results support

147 including 2018 participants with type 1 and type 2 diabetes diagnosed at younger than 20 years, with

148 Among adults with type 2 diabetes diagnosed for less than 10 years, a life

149 elopments in the diagnosis and management of type 2 diabetes, existing controversies, and future dire

150 eing significantly associated with prevalent type 2 diabetes for participants with high dietary fat i

151 ypertension risks, using 3,448 patients with type 2 diabetes from the ADVANCE study (Action in Diabet

152 AEs for osteoporosis, hypertension, obesity, type 2 diabetes, gastrointestinal ulcers/bleeds, fractur

153 old woman with a history of hypertension and type 2 diabetes had been in her usual state of health un

154 Finally, monocytes from patients with type 2 diabetes had increased Mll1 compared with control

155 diabetes and controls, whereas patients with type 2 diabetes had smaller reductions in fatal outcomes

156 h type 1 diabetes and 42.2% of patients with type 2 diabetes had undergone an eye examination by 6 ye

157 e, evidence is accumulating that young-onset type 2 diabetes has a more aggressive disease phenotype,

158 cent obesity, an unprecedented phenomenon of type 2 diabetes has emerged in pediatrics.

159 Finally, we found that patients with type 2 diabetes have reticulated thrombocytosis that cor

160 Studies in animal models of type 2 diabetes have shown that glucagon-like peptide 1

161 s such as asthma, food allergies, type 1 and type 2 diabetes, hepatic steatosis, cardiovascular disea

162 ological treatment options are available for type 2 diabetes; however, many patients do not achieve o

163 ction against metabolic syndromes, including type 2 diabetes; however, mechanisms that are associated

164 s, and 12 years to ascertain the presence of type 2 diabetes, hypertension, and dyslipidemia.

165 The prevalence of type 2 diabetes in adolescents and young adults is drama

166 s emerging evidence on the increased risk of type 2 diabetes in association with antidepressant use.

167 ain, at least in part, the increased risk of type 2 diabetes in p.P50T/AKT2 carriers.

168 ubcutaneous insulin therapy in patients with type 2 diabetes in the general ward.

169 antidepressant use and the risk of incident type 2 diabetes in youths by antidepressant subclass and

170 a new drug target for insulin resistance in Type-2 diabetes, in which the unmet therapeutic need rem

171 currently using SSRIs or SNRIs, the risk of type 2 diabetes increased with the duration of use (RR,

172 Remission of type 2 diabetes is a practical target for primary care.

173 Type 2 diabetes is an independent risk factor for both s

174 The onset of type 2 diabetes is characterized by transition from succ

175 Virus-related type 2 diabetes is commonly observed in individuals infe

176 A hallmark of type 2 diabetes is impaired insulin receptor (IR) signal

177 rial fibrillation, and in the setting of AF, type 2 diabetes is independently associated with a 2% to

178 Type 2 diabetes is often accompanied by dyslipidemia wit

179 Type 2 diabetes is thought to involve a compromised beta

180 tive vascular smooth muscle from humans with type 2 diabetes is unclear.

181 Type 2 diabetes leads to premature death and reduced qua

182 At the heart of the development of type 2 diabetes lies a key metabolic derangement: insuli

183 %]; 4505 white [82.6%]) and 7233 youths with type 2 diabetes (median age at initial diagnosis, 19 yea

184 Prevalence of type 2 diabetes mellitus (15.5%-5.9%), hypertension (29.

185 assessed the first documented occurrence of type 2 diabetes mellitus (DM), chronic kidney disease (C

186 Over the past decades, the prevalence of type 2 diabetes mellitus (T2D) has been steadily increas

187 ividual CC lines were identified that showed type 2 diabetes mellitus (t2DM) development and signific

188 on between fruit consumption and the risk of type 2 diabetes mellitus (T2DM) have been inconsistent.W

189 In type 2 diabetes mellitus (T2DM) patients (n = 38), the l

190 However, endurance trained athletes and type 2 diabetes mellitus (T2DM) patients store similar a

191 ion, BMP-9 was independently associated with type 2 diabetes mellitus (T2DM), HOMA-IR and FFA.

192 omising drug candidates for the treatment of Type 2 diabetes mellitus (T2DM).

193 ance leads to hyperglycemia, the hallmark of type 2 diabetes mellitus (T2DM).

194 ular and heart failure risk in patients with type 2 diabetes mellitus (T2DM).

195 lar morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular

196 tively associated with age, body mass index, type 2 diabetes mellitus and inversely with estimated gl

197 Patients with type 2 diabetes mellitus and prior cardiovascular events

198 Secretion of this hormone is dysregulated in type 2 diabetes mellitus but the mechanisms controlling

199 ines for glycated hemoglobin A1c testing for type 2 diabetes mellitus could be improved to bring them

200 at baseline, of whom 67% had a diagnosis of type 2 diabetes mellitus for >10 years, 58% were receivi

201 m METASTROKE (12 389 ischemic stroke cases), type 2 diabetes mellitus from DIAGRAM (Diabetes Genetics

202 Type 2 diabetes mellitus is a complex disease affecting

203 in a post hoc analysis in 1147 patients with type 2 diabetes mellitus on hemodialysis who participate

204 flozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).

205 ) randomly assigned 10 142 participants with type 2 diabetes mellitus to canagliflozin or placebo.

206 ease, spanning conditions such as obesity to type 2 diabetes mellitus with excess cardiovascular risk

207 ed a substantial proportion of patients with type 2 diabetes mellitus without clinically recognized e

208 nd adipokine abnormalities (the hallmarks of type 2 diabetes mellitus) are characteristic features of

209 of islet-amyloid polypeptide associated with type 2 diabetes mellitus, a-synuclein associated with Pa

210 ted States, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascular disease.

211 chronic hypertension, hypercholesterolemia, type 2 diabetes mellitus, and changes in body mass index

212 metformin, a first-line therapeutic drug for type 2 diabetes mellitus, and nelfinavir, an HIV proteas

213 preclinical candidates for the treatment of type 2 diabetes mellitus, as well as a promising startin

214 flozin on clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular dis

215 atic beta cell function underlies type 1 and type 2 diabetes mellitus.

216 ic therapy for hypertension in patients with Type 2 diabetes mellitus.

217 uctose consumption in people with type 1 and type 2 diabetes mellitus.

218 st promising strategies for the treatment of type 2 diabetes mellitus.

219 ences encountered by patients suffering from type 2 Diabetes Mellitus.

220 Erythrocytes in patients with type-2 diabetes mellitus (T2DM) are associated with redu

221 A (n = 50) from type 1 diabetes (n = 50) and type 2 diabetes (n = 50).

222 ugh overall still a rare disease, adolescent type 2 diabetes now poses major challenges to paediatric

223 was associated with a 2% increase in risk of type 2 diabetes (odds ratio 1.02, 95% CI 1.01-1.03, P =

224 -12)), ulcerative colitis (P<1.0 x 10(-20)), type 2 diabetes (P=2.8 x 10(-13)), hip/waist circumferen

225 dy mass index (P=2.2x10(-5)) and the risk of type 2 diabetes (P=6.1x10(-4)) associated with the risk

226 current hyperglycemia and infection risk in type 2 diabetes patients.

227 were exclusively identified in the serum of type 2 diabetes patients.

228 After matching for age, sex, hypertension, type 2 diabetes, previous stroke, and anticoagulation, i

229 We assessed the relative risk of type 2 diabetes prospectively for each cohort and lipid

230 Despite recommendations, many patients with type 2 diabetes receive dietary advice from nurses or do

231 is of a clinical trial in 1450 patients with type 2 diabetes receiving metformin and randomly assigne

232 mine the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of i

233 operties of metformin, a first-line drug for type 2 diabetes, remain elusive.

234 y group who had type 2 diabetes at baseline, type 2 diabetes remitted in 66 of 88 patients (75%) at 2

235 tty liver disease, hazardous alcohol use, or type 2 diabetes, reported higher prevalence of advanced

236 The treatment of type 2 diabetes requires positive modulation of GLP-1R t

237 Aging is associated with increased risk for type 2 diabetes, resulting from reduced insulin sensitiv

238 Type 2 diabetes results from defects in both insulin sen

239 mated (BMI increasing) associations among 11 type 2 diabetes risk alleles (at P < 0.05).

240 and environmental determinants of type 1 and type 2 diabetes risk and progression, as well as complic

241 arker were not significantly associated with type 2 diabetes risk overall (RR per interquintile range

242 cretion but has no evidence for an effect on type 2 diabetes risk.

243 In contrast, chronic hypertension and type 2 diabetes showed no significant associations.

244 1, 118 unique associations between published type 2 diabetes single nucleotide polymorphisms (SNPs) a

245 expression when compared to neutrophils from type 2 diabetes subjects.

246 production of sclerostin in mouse models of type 2 diabetes, suggest an endocrine function.

247 Although a large proportion of patients with type 2 diabetes (T2D) accumulate misfolded aggregates co

248 cated hemoglobin (HbA1c) is used to diagnose type 2 diabetes (T2D) and assess glycemic control in pat

249 Obesity and associated type 2 diabetes (T2D) are important risk factors for inf

250 change in islet mass in different stages of type 2 diabetes (T2D) as measured by noninvasive imaging

251 Type 2 diabetes (T2D) has attained the status of a globa

252 Type 2 diabetes (T2D) has many cardiovascular complicati

253 f a combination of fatty acids with incident type 2 diabetes (T2D) has not been evaluated.

254 ew genome-wide association studies (GWAS) of type 2 diabetes (T2D) have been conducted in U.S Hispani

255 , and has been approved for the treatment of type 2 diabetes (T2D) in clinic.

256 isk in cohort studies, while the relation to type 2 diabetes (T2D) in the elderly remains unclear.

257 x hormones (ESH) are associated with risk of type 2 diabetes (T2D) in women.

258 The effect of Copy Number Variants (CNVs) on Type 2 Diabetes (T2D) remains little explored.

259 Bariatric surgery promotes type 2 diabetes (T2D) remission through a succession of

260 CVD is more prevalent in type 2 diabetes (T2D) than type 1 diabetes (T1D), but th

261 GLP-1) receptor (GLP-1R) is a key target for type 2 diabetes (T2D) treatment.

262 beta-Cell failure in type 2 diabetes (T2D) was recently proposed to involve d

263 polypeptide (IAPP), which is associated with type 2 diabetes (T2D), with the Alzheimer's disease amyl

264 To characterize type 2 diabetes (T2D)-associated variation across the al

265 uconeogenesis is also a signature feature of type 2 diabetes (T2D).

266 ects with classical and early-onset forms of type 2 diabetes (T2D).

267 onment on the individual risk of obesity and Type 2 Diabetes (T2D).

268 species are associated with pathogenesis of type 2 diabetes (T2D).

269 lin secretion is an early sign of developing type 2 diabetes (T2D).

270 reported to contribute to the development of type 2 diabetes (T2D).

271 n saturated fatty acids and the incidence of type 2 diabetes (T2D).A prospective cohort analysis of 3

272 glucose and plasma insulin in patients with type 2 diabetes (T2D).A randomized crossover clinical tr

273 reduction of macrovascular complications in type 2 diabetes (T2D); however, the underlying mechanism

274 mediators in cardiovascular complications of type 2 diabetes (T2D); however, their contribution to Ch

275 ation, is associated with beta-cell death in type-2 diabetes (T2D).

276 Obesity and type 2 diabetes(T2D) are the most prevalent and serious

277 lux is associated with future development of type 2 diabetes (T2DM) in cardiovascular patients.

278 surgery procedures according to severity of type 2 diabetes (T2DM).

279 atal outcomes declined less among those with type 2 diabetes than among controls.

280 LADA was more similar to type 2 diabetes than to type 1 diabetes.

281 ass-was associated with an increased risk of type 2 diabetes that intensified with increasing duratio

282 Similar to older-onset type 2 diabetes, the major predisposing risk factors are

283 min, an anti-diabetic drug commonly used for type 2 diabetes therapy, is associated with anti-angioge

284 cs of type 1 diabetes differed from those of type 2 diabetes: they had a lower BMI (27.4 kg/m(2) [95%

285 ceived multiple daily insulin injections for type 2 diabetes used CGM on a daily or near-daily basis

286 blood pressure, coronary artery disease, and type 2 diabetes using data from six independent GWAS con

287 actors measured over time, participants with type 2 diabetes vs those with type 1 had significantly h

288 rated health, smoking status, triglycerides, type 2 diabetes, waist-hip ratio, attention deficit hype

289 ght, obesity, smoking status, triglycerides, type 2 diabetes, waist-hip ratio, childhood cognitive ab

290 Incident type 2 diabetes was assessed using discrete-time failure

291 The risk of type 2 diabetes was significantly greater during current

292 In this longitudinal study of patients with type 2 diabetes, we found no association between TZD use

293 associated with a reduced risk of developing type 2 diabetes.We tested whether pomegranate polyphenol

294 nicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to

295 present in more than 90% of individuals with type 2 diabetes, where it contributes to beta-cell apopt

296 eful biomarker for identifying patients with type 2 diabetes who are at risk for developing AD.

297 th cognitive function in older patients with type 2 diabetes who are carriers of the haptoglobin (Hp)

298 To induce type 2 diabetes, wild-type (WT), p40IL-12(-/-) (p40(-/-)

299 e National Eye Center among 50 patients with type 2 diabetes with and without DR (n = 100 eyes).

300 sed to examine the eyes of participants with type 2 diabetes with or without DR and the eyes of parti